GU Cancers 2020 | KRAS G12C target for urothelial carcinoma
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Petros Grivas, MD, PhD, University of Washington, Seattle, WA, discusses KRAS G12C as an emerging target for urothelial carcinoma and the ongoing research into this rare, although important mutation. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up